Annual CFF
-$211.79 M
+$782.00 K+0.37%
December 31, 2024
Summary
- As of March 12, 2025, AMRX annual cash flow from financing activities is -$211.79 million, with the most recent change of +$782.00 thousand (+0.37%) on December 31, 2024.
- During the last 3 years, AMRX annual CFF has fallen by -$73.67 million (-53.34%).
- AMRX annual CFF is now -173.62% below its all-time high of $287.68 million, reached on December 31, 2018.
Performance
AMRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$61.20 M
+$31.14 M+33.72%
December 31, 2024
Summary
- As of March 12, 2025, AMRX quarterly cash flow from financing activities is -$61.20 million, with the most recent change of +$31.14 million (+33.72%) on December 31, 2024.
- Over the past year, AMRX quarterly CFF has stayed the same.
- AMRX quarterly CFF is now -113.08% below its all-time high of $467.98 million, reached on March 31, 2020.
Performance
AMRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$211.79 M
+$39.63 M+15.76%
December 31, 2024
Summary
- As of March 12, 2025, AMRX TTM cash flow from financing activities is -$211.79 million, with the most recent change of +$39.63 million (+15.76%) on December 31, 2024.
- Over the past year, AMRX TTM CFF has stayed the same.
- AMRX TTM CFF is now -141.81% below its all-time high of $506.60 million, reached on September 30, 2018.
Performance
AMRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AMRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +0.4% | 0.0% | 0.0% |
| 3 y3 years | -53.3% | -32.7% | -84.5% |
| 5 y5 years | -362.1% | -442.5% | -260.7% |
AMRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -98.6% | +0.4% | -363.3% | +39.3% | -265.5% | +15.8% |
| 5 y | 5-year | -260.7% | +0.4% | -113.1% | +80.3% | -147.7% | +41.5% |
| alltime | all time | -173.6% | +0.4% | -113.1% | +80.3% | -141.8% | +41.5% |
Amneal Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$211.79 M(-0.4%) | -$61.20 M(-33.7%) | -$211.79 M(-15.8%) |
| Sep 2024 | - | -$92.35 M(+163.2%) | -$251.42 M(+2.3%) |
| Jun 2024 | - | -$35.09 M(+51.5%) | -$245.66 M(+10.2%) |
| Mar 2024 | - | -$23.16 M(-77.0%) | -$222.83 M(+4.8%) |
| Dec 2023 | -$212.57 M(+99.4%) | -$100.83 M(+16.5%) | -$212.57 M(+58.7%) |
| Sep 2023 | - | -$86.58 M(+606.5%) | -$133.91 M(+43.3%) |
| Jun 2023 | - | -$12.26 M(-5.0%) | -$93.45 M(+61.3%) |
| Mar 2023 | - | -$12.90 M(-41.8%) | -$57.95 M(-45.6%) |
| Dec 2022 | -$106.62 M(-22.8%) | -$22.17 M(-51.9%) | -$106.62 M(-7.1%) |
| Sep 2022 | - | -$46.13 M(-298.4%) | -$114.80 M(+2.3%) |
| Jun 2022 | - | $23.25 M(-137.8%) | -$112.23 M(-35.3%) |
| Mar 2022 | - | -$61.57 M(+102.9%) | -$173.54 M(+25.6%) |
| Dec 2021 | -$138.12 M | -$30.35 M(-30.3%) | -$138.12 M(+16.0%) |
| Sep 2021 | - | -$43.55 M(+14.4%) | -$119.05 M(+31.8%) |
| Jun 2021 | - | -$38.07 M(+45.6%) | -$90.31 M(-75.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | -$26.15 M(+131.8%) | -$362.32 M(-374.9%) |
| Dec 2020 | $131.81 M(-387.6%) | -$11.28 M(-23.8%) | $131.81 M(-2.9%) |
| Sep 2020 | - | -$14.81 M(-95.2%) | $135.79 M(-5.0%) |
| Jun 2020 | - | -$310.08 M(-166.3%) | $143.00 M(-67.8%) |
| Mar 2020 | - | $467.98 M(-6512.4%) | $444.01 M(-1068.8%) |
| Dec 2019 | -$45.83 M(-115.9%) | -$7.30 M(-3.9%) | -$45.83 M(-82.2%) |
| Sep 2019 | - | -$7.60 M(-16.3%) | -$257.45 M(+53.9%) |
| Jun 2019 | - | -$9.07 M(-58.5%) | -$167.26 M(-155.9%) |
| Mar 2019 | - | -$21.86 M(-90.0%) | $299.06 M(+4.0%) |
| Dec 2018 | $287.68 M(-402.8%) | -$218.92 M(-365.0%) | $287.68 M(-43.2%) |
| Sep 2018 | - | $82.60 M(-81.9%) | $506.60 M(+19.5%) |
| Jun 2018 | - | $457.24 M(-1475.3%) | $424.00 M(-1375.3%) |
| Mar 2018 | - | -$33.25 M | -$33.25 M |
| Dec 2017 | -$95.02 M(+387.4%) | - | - |
| Dec 2016 | -$19.50 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual CFF year-on-year change?
- What is Amneal Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly CFF year-on-year change?
- What is Amneal Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM CFF year-on-year change?
What is Amneal Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AMRX is -$211.79 M
What is the all time high annual CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual cash flow from financing activities is $287.68 M
What is Amneal Pharmaceuticals annual CFF year-on-year change?
Over the past year, AMRX annual cash flow from financing activities has changed by +$782.00 K (+0.37%)
What is Amneal Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AMRX is -$61.20 M
What is the all time high quarterly CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly cash flow from financing activities is $467.98 M
What is Amneal Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AMRX quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Amneal Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AMRX is -$211.79 M
What is the all time high TTM CFF for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM cash flow from financing activities is $506.60 M
What is Amneal Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AMRX TTM cash flow from financing activities has changed by $0.00 (0.00%)